Validation period: 8/8/2022, 8:10:02 AM - 9/7/2022, 6:10:02 PM
BMJ Journals logo
Home/Top cited articles
Email alerts

Top cited articles

Acceptance rate:
17%
Time to first decision with review:
27 days*
Acceptance to publication:
9 days*
Impact Factor (JCR):
27.973
Impact Factor rank (JCR):
3/34
Citescore:
28.5
*median number of days
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Smolen, Josef S; Landewe, Robert B. M; Bijlsma, Johannes W. J; et al 10.1136/annrheumdis-2019-216655 Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry Gianfrancesco, Milena; Hyrich, Kimme L.; Al-Adely, Sarah; et al 10.1136/annrheumdis-2020-217871 Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study Furer, Victoria; Eviatar, Tali; Zisman, Devy; et al 10.1136/annrheumdis-2021-220647 Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry Strangfeld, Anja; Schafer, Martin; Gianfrancesco, Milena A; et al 10.1136/annrheumdis-2020-219498 Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017 Safiri, Saeid; Kolahi, Ali-Asghar; Smith, Emma; et al 10.1136/annrheumdis-2019-216515 2018 Update of the EULAR recommendations for the management of large vessel vasculitis Hellmich, Bernhard; Agueda, Ana; Monti, Sara; et al 10.1136/annrheumdis-2019-215672 EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update Gossec, Laure; Baraliakos, Xenofon; Kerschbaumer, Andreas; et al 10.1136/annrheumdis-2020-217159 Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort Geisen, Ulf M; Berner, Dennis K; Tran, Florian; et al 10.1136/annrheumdis-2021-220272 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis Fanouriakis, Antonis; Kostopoulou, Myrto; Cheema, Kim; et al 10.1136/annrheumdis-2020-216924 Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease Haberman, Rebecca H; Herati, Ramin Sedaghat; Simon, David; et al 10.1136/annrheumdis-2021-220597 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases Furer, Victoria; Rondaan, Christien; Heijstek, Marloes W; et al 10.1136/annrheumdis-2019-215882 Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression Prendecki, Maria; Clarke, Candice; Edwards, Helena; et al 10.1136/annrheumdis-2021-220626 Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2 Braun-Moscovici, Yolanda; Kaplan, Marielle; Braun, Maya; et al 10.1136/annrheumdis-2021-220503 Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort Pouletty, Marie; Borocco, Charlotte; Ouldali, Naim; et al 10.1136/annrheumdis-2020-217960 SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases Simon, David; Tascilar, Koray; Fagni, Filippo; et al 10.1136/annrheumdis-2021-220461 Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis Akiyama, Shintaro; Hamdeh, Shadi; Micic, Dejan;et al 10.1136/annrheumdis-2020-218946 SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity Mrak, Daniel; Tobudic, Selma; Koblischke, Maximilian; et al 10.1136/annrheumdis-2021-220781 Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases Spiera, Robert; Jinich, Sarah; Jannat-Khah, Deanna 10.1136/annrheumdis-2021-220604 Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases Boyarsky, Brian J; Ruddy, Jake A; Connolly, Caoilfhionn M; et al 10.1136/annrheumdis-2021-220289 EULAR recommendations for the management of Sjogren’s syndrome with topical and systemic therapies Ramos-Casals, Manuel; Brito-Zeron, Pilar; Bombardieri, Stefano; et al 10.1136/annrheumdis-2019-216114
eular-75 logoeular-textbooks logo
CONTENTrss-icontwitter-iconfacebook-iconsoundcloud-iconyoutube-icon
bmj-footer-logo
Website Terms & ConditionsPrivacy & CookiesContact BMJCookie settingsOnline ISSN: 1468-2060 Print ISSN: 0003-4967Copyright © 2022 BMJ Publishing Group Ltd & European Alliance of Associations for Rheumatism. All rights reserved.